# US 2025/0152629 A1 · Compositions including killer innate-like t cells and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0152629 A1
- Document ID: US20250152629A1
- Status: Published application
- Kind: A1
- Application number: 18/838,592
- Filed: 2023-02-14
- Published: 2025-05-15
- Earliest claimed: 2022-02-15
- Applicants: Memorial Sloan-Kettering Cancer Center; Memorial Hospital for Cancer and Allied Diseases; Sloan-Kettering Institute for Cancer Research
- Inventors: Ming Li; Chun Chou; Xian Zhang; Saida Dadi; Briana G. Nixon; Jing Zhang
- Web page: https://patentgrep.com/patent/US20250152629A1

## CPC

- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 38/2086: {IL-13 to IL-16}
- A61K 40/15: Natural-killer [NK] cells; Natural-killer T [NKT] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4211: {CD19 or B4}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07K 16/2803: {against the immunoglobulin superfamily}
- C12N 5/0646: {Natural killers cells [NK], NKT cells}
- C12N 15/86: Viral vectors
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- A61K 2239/13: Antibody-based
- A61K 2239/21: Transmembrane domain
- A61K 2239/22: Intracellular domain
- C12N 15/85: for animal cells
- C12N 2740/10043: viral genome or elements thereof as genetic vector
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Described herein are compositions including killer innate-like T cells (ILTCks), methods for preparing IL TCks for adoptive cell therapy, an methods of using IL TCks to treat cancer. Further, wherein an engineered killer innate-like T cell (ILTCk) comprises a non-endogenous expression vector including a mammalian IL-15 nucleic acid sequence or a mammalian STAT5B nucleic acid sequence is disclosed.

## Claims

### Claim 1

An engineered killer innate-like T cell (ILTCk) comprising a non-endogenous expression vector including a mammalian TL-15 nucleic acid sequence or a mammalian STAT5B nucleic acid sequence, wherein the IL-15 nucleic acid sequence or the STAT5B nucleic acid sequence is operably linked to an expression control sequence, optionally wherein the engineered TLC is derived from an autologous donor or an allogenic donor.

### Claim 2 (depends on 1)

The engineered ILTCk of claim 1, wherein the expression control sequence comprises an inducible promoter, a constitutive promoter, a native IL-15 or STAT5B promoter, or a heterologous promoter; or
wherein the non-endogenous expression vector is a plasmid, a cosmid, a bacmid, a bacterial artificial chromosome (BAC), a yeast artificial chromosome (YAC), a viral vector, or a retroviral vector; or
wherein the IL-15 nucleic acid sequence encodes the amino acid sequence of SEQ ID NO: 19 or SEQ ID NO: 20; or
wherein the STAT5B nucleic acid sequence encodes the amino acid sequence of SEQ ID NO: 9 or SEQ ID NO: 23.

### Claim 3

(canceled)

### Claim 4

(canceled)

### Claim 5

(canceled)

### Claim 6 (depends on 1)

The engineered ILTCk of claim 1, further comprising a chimeric antigen receptor (CAR) that binds to a tumor antigen and/or a nucleic acid encoding the CAR, optionally wherein the heterologous promoter is induced by binding of the CAR to the tumor antigen, or wherein binding of the CAR to the tumor antigen results in antigen-dependent JAK-STAT5 pathway activation: or
wherein the CAR comprises (i) an extracellular antigen binding domain: (ii) a transmembrane domain; and (iii) an intracellular domain comprising one or more co-stimulatory domains, wherein the extracellular antigen binding domain binds to the tumor antigen.

### Claim 7

(canceled)

### Claim 8

(canceled)

### Claim 9

An engineered killer innate-like T cell (ILTCk) comprising a chimeric antigen receptor (CAR) that binds to a tumor antigen, wherein the CAR comprises (i) an extracellular antigen binding domain that binds to the tumor antigen; (ii) a transmembrane domain; and (iii) an intracellular domain comprising a truncated cytoplasmic domain of IL-2RβΔ and one or more co-stimulatory domains, optionally wherein the truncated cytoplasmic domain of IL-2RβΔ comprises the amino acid sequence of SEQ ID NO: 7.

### Claim 10

(canceled)

### Claim 11 (depends on 6)

The engineered ILTCk of claim 6, wherein the extracellular antigen binding fragment comprises a single-chain variable fragment (scFv), optionally wherein the scFv is human: or
wherein the tumor antigen is selected from the group consisting of 5T4, alpha 5P1-integrin, 707-AP, AFP, ART-4, B7H4, BCMA, Bcr-abl, CA125, CA19-9, CDH1, CDH17, CAMEL, CAP-1, CASP-8, CD5, CD25, CDC27/m, CD37, CD52, CDK4/m, c-Met, CS-1, CT, Cyp-B, cyclin B1, DAGE, DAM, EBNA, ErbB3, ELF2M, EMMPRIN, ephrinB2, estrogen receptor, ETV6-AML1, FAP, ferritin, folate-binding protein, G250, GM2, HAGE, HLA-A*0201-R170I, HPV E6, HPV E7, HSP70-2M, HST-2, hTERT (or hTRT), iCE, IL-2R, IL-5, KIAA0205, LAGE, LDLR/FUT, MART-1/melan-A, MART-2/Ski, MC1R, mesothelin, MUC16, myc, MUM-2, MUM-3, NA88-A, NYESO-1, NY-Eso-B, proteinase-3, p190 minor bcr-abl, Pml/RARa, progesterone receptor, PSCA, RU1 or RU2, RORI, SART-1 or SART-3, survivin, TEL/AML1, TGFβ, TPI/m, TRP-1, TRP-2, TRP-2/INT2, tenascin, TSTA tyrosinase, CD3, GPA33, HER2/neu, GD2, MAGE-1, MAGE-3, BAGE, GAGE-1, GAGE-2, MUM-1, CDK4, N-acetylglucosaminyltransferase, p15, gp75, beta-catenin, ErbB2, cancer antigen 125 (CA-125), carcinoembryonic antigen (CEA), RAGE, MART (melanoma antigen), MUC-1, MUC-2, MUC-3, MUC-4, MUC-5ac, MUC-16, MUC-17, tyrosinase, Pmel 17 (gp100), GnT-V intron V sequence (N-acetylglucoaminyltransferase V intron V sequence), Prostate cancer psm, PRAME (melanoma antigen), β-catenin, EBNA (Epstein-Barr Virus nuclear antigen) 1-6, LMP2, p53, lung resistance protein (LRP), Bcl-2, prostate specific antigen (PSA), Ki-67, CEACAM6, colon-specific antigen-p (CSAp), HLA-DR, CD40, CD74, CD138, EGFR, EGP-1, EGP-2, VEGF, PlGF, insulin-like growth factor (ILGF), tenascin, platelet-derived growth factor, IL-6, CD20, CD19, PSMA, CD33, CD123, MET, DLL4, Ang-2, HER3, IGF-1R, CD30, TAG-72, SPEAP, CD45, L1-CAM, Lewis Y (Ley) antigen, E-cadherin, V-cadherin, GPC3, EpCAM, CD4, CD8, CD21, CD23, CD46, CD80, HLA-DR, CD74, CD22, CD14, CD15, CD16, CD123, TCR gamma/delta, NKp46, KIR, CD56, DLL3, PD-1, PD-L1, CD28, CD137, CD99, GloboH, CD24, STEAPI, B7H3, Polysialic Acid, OX40, OX40-ligand, and peptide MHC complexes (with peptides derived from TP53, KRAS, MYC, EBNA1-6, PRAME, tyronsinase, MAGEAI-A6, pmel17, LMP2, or WT1).

### Claim 12

(canceled)

### Claim 13

(canceled)

### Claim 14 (depends on 6)

The engineered ILTCk of claim 6, wherein the transmembrane domain comprises a CD8 transmembrane domain, a CD28 transmembrane domain, a NKG2D transmembrane domain, a CD3ζ transmembrane domain, a CD4 transmembrane domain, a 4-1BB transmembrane domain, an OX40 transmembrane domain, an ICOS transmembrane domain, a CTLA-4 transmembrane domain, a PD-1 transmembrane domain, a LAG-3 transmembrane domain, a 2B4 transmembrane domain, or a BTLA transmembrane domain; or
wherein the one or more co-stimulatory domains are selected from the group consisting of a CD28 co-stimulatory domain, a 4-1BB co-stimulatory domain, an OX40 co-stimulatory domain, an ICOS co-stimulatory domain, a DAP-10 co-stimulatory domain, a PD-1 co-stimulatory domain, a CTLA-4 co-stimulatory domain, a LAG-3 co-stimulatory domain, a 2B4 co-stimulatory domain, a BTLA co-stimulatory domain, a NKG2C co-stimulatory domain, a NKG2D co-stimulatory domain, and any combination thereof; or
wherein the one or more co-stimulatory domains comprise a DAP-10 co-stimulatory domain and a 2B4 co-stimulatory domain.

### Claim 15

(canceled)

### Claim 16

(canceled)

### Claim 17

(canceled)

### Claim 18 (depends on 1)

A composition comprising an effective amount of the engineered ILTCk of claim 1 and a pharmaceutically acceptable carrier.

### Claim 19 (depends on 1)

A method of preparing the engineered ILTCk of claim 1 for adoptive cell therapy comprising: (a) isolating killer innate-like T cells (ILTCks) from a donor subject, (b) transducing the ILTCks with a nucleic acid encoding IL-15 or STAT5B or an expression vector comprising said nucleic acid, and (c) administering the transduced ILTCks to a recipient subject, optionally wherein
the nucleic acid encodes the amino acid sequence of SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 9 or SEQ ID NO: 23, or wherein the donor subject and the recipient subject are the same or different; or
isolating ILTCks from the donor subject comprises isolating a population of immune cells from the donor subject, and collecting FCER1G+ cells from the isolated population of immune cells.

### Claim 20

(canceled)

### Claim 21 (depends on 19)

The method of claim 19, further comprising
transducing the ILTCks with a nucleic acid encoding a chimeric antigen receptor (CAR) that binds to a tumor antigen; or
transducing the ILTCks with a nucleic acid encoding a chimeric antigen receptor (CAR) that binds to a tumor antigen or an expression vector comprising said nucleic acid, wherein the CAR comprises (i) an extracellular antigen binding domain that binds to the tumor antigen: (ii) a transmembrane domain; and (iii) an intracellular domain comprising a truncated cytoplasmic domain of IL-2RβΔ and one or more co-stimulatory domains.

### Claim 22

(canceled)

### Claim 23

(canceled)

### Claim 24 (depends on 1)

A method for treating cancer or inhibiting tumor growth in a subject in need thereof comprising administering to the subject an effective amount of the engineered ILTCk of claim 1, optionally wherein the cancer or tumor is selected from the group consisting of adrenal cancers, bladder cancers, blood cancers, bone cancers, brain cancers, breast cancers, carcinoma, cervical cancers, colon cancers, colorectal cancers, corpus uterine cancers, ear, nose and throat (ENT) cancers, endometrial cancers, esophageal cancers, gastrointestinal cancers, head and neck cancers, Hodgkin's disease, intestinal cancers, kidney cancers, larynx cancers, acute and chronic leukemias, liver cancers, lymph node cancers, lymphomas, lung cancers, melanomas, mesothelioma, myelomas, nasopharynx cancers, neuroblastomas, non-Hodgkin's lymphoma, oral cancers, ovarian cancers, pancreatic cancers, penile cancers, pharynx cancers, prostate cancers, rectal cancers, sarcoma, seminomas, skin cancers, stomach cancers, teratomas, testicular cancers, thyroid cancers, uterine cancers, vaginal cancers, vascular tumors, and metastases thereof; or wherein the engineered ILTCk is administered pleurally, intravenously, subcutaneously, intranodally, intratumorally, intrathecally, intrapleurally or intraperitoneally.

### Claim 25

(canceled)

### Claim 26

(canceled)

### Claim 27 (depends on 24)

The method of claim 24, further comprising sequentially, separately, or simultaneously administering to the subject an additional cancer therapy, optionally wherein the additional cancer therapy is selected from among chemotherapeutic agents, immune checkpoint inhibitors, monoclonal antibodies that specifically target tumor antigens, immune activating agents (e.g., interferons, interleukins, cytokines), oncolytic virus therapy and cancer vaccines.

### Claim 28

(canceled)

### Claim 29 (depends on 1)

A kit for preparing the engineered ILTCk of claim 1 comprising an expression vector that includes a nucleic acid sequence encoding an amino acid sequence of SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 9 or SEQ ID NO: 23 and instructions for transducing ILTCks with the expression vector, and optionally a vector encoding an engineered CAR or other cell-surface ligand that binds to a tumor antigen.

### Claim 30

(canceled)

### Claim 31

(canceled)

### Claim 32

(canceled)

### Claim 33

(canceled)

### Claim 34

(canceled)

### Claim 35

A method for treating cancer or inhibiting tumor growth in a subject in need thereof comprising administering to the subject an effective amount of killer innate-like T cells (ILTCks), optionally wherein
the ILTCks are native ILTCks, genetically engineered ILTCks, or a combination thereof; or
the ILTCks are isolated from a donor subject and/or expanded ex vivo or in vitro: or
the subject harbors tumors with low mutation burden.

### Claim 36

(canceled)

### Claim 37

(canceled)

### Claim 38 (depends on 32)

The method of claim 32, further comprising separately, simultaneously, or sequentially administering an effective amount of IL-15 to the subject, optionally wherein the IL-15 is administered to the subject prior to, during, or subsequent to administration of the ILTCks.

### Claim 39

(canceled)

### Claim 40 (depends on 32)

The method of claim 32, wherein the cancer or tumor is selected from the group consisting of adrenal cancers, bladder cancers, blood cancers, bone cancers, brain cancers, breast cancers, carcinoma, cervical cancers, colon cancers, colorectal cancers, corpus uterine cancers, ear, nose and throat (ENT) cancers, endometrial cancers, esophageal cancers, gastrointestinal cancers, head and neck cancers, Hodgkin's disease, intestinal cancers, kidney cancers, larynx cancers, acute and chronic leukemias, liver cancers, lymph node cancers, lymphomas, lung cancers, melanomas, mesothelioma, myelomas, nasopharynx cancers, neuroblastomas, non-Hodgkin's lymphoma, oral cancers, ovarian cancers, pancreatic cancers, penile cancers, pharynx cancers, prostate cancers, rectal cancers, sarcoma, seminomas, skin cancers, stomach cancers, teratomas, testicular cancers, thyroid cancers, uterine cancers, vaginal cancers, vascular tumors, and metastases thereof; or wherein the ILTCks are administered pleurally, intravenously, subcutaneously, intranodally, intratumorally, intrathecally, intrapleurally or intraperitoneally.

### Claim 41

(canceled)

### Claim 42 (depends on 32)

The method of claim 32, further comprising sequentially, separately, or simultaneously administering to the subject an additional cancer therapy, optionally wherein the additional cancer therapy is selected from among chemotherapeutic agents, immune checkpoint inhibitors, monoclonal antibodies that specifically target tumor antigens, immune activating agents (e.g., interferons, interleukins, cytokines), oncolytic virus therapy and cancer vaccines.

### Claim 43

(canceled)

### Claim 44 (depends on 35)

The method of claim 35, further comprising
isolating a population of immune cells from a donor subject, and
collecting FCER1G+ cells from the isolated population of immune cells to obtain ILTCks.

### Claim 45 (depends on 44)

The method of claim 44, wherein the FCER1G+ cells comprise FCER1G+ CD122+ cells, FCER1G+ NK1.1+GzmB+/− cells, FCER1G+NK1.1−GzmB− cells, and/or FCER1G+ PD-1+ cells.

### Claim 46 (depends on 35)

The method of claim 35, wherein the tumors with low mutation burden are identified via next-generation sequencing using a tumor biopsy sample or cell-free DNA (cfDNA) sample obtained from the cancer subject; or wherein the tumors are refractory to immune checkpoint blockade therapy or adoptive cell therapy with CD8+ T cell therapy.
